Reprogramming the immune suppressive tumor microenvironment in glioma enhances the efficacy of immune-mediated gene therapy
Molecular Therapy Oncology · 2026-06 · 34 (2) · 201215
DOI: 10.1016/j.omton.2026.201215 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Oncology, 2026-06. Verfasst von Brandon L McClellan und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Cancer Institute, Leah's Happy Hearts, University of Michigan Rackham Graduate School.
Abstract (Originalsprache)
Gliomas account for ∼80% of primary malignant brain tumors. Many CNS WHO grade 2-3 and some grade 4 gliomas harbor mutant isocitrate dehydrogenase 1 (mIDH1), which causes a gain-of-function mutation (IDH1 R132H) leading to the production of 2-hydroxyglutarate (2HG). Mutant IDH1-induced 2HG, through epigenetic reprogramming elicits an immune-permissive tumor microenvironment (TME). An immunosuppressive mechanism in the glioma TME involves adenosine production via the ectoenzyme CD73. This study investigates mIDH1's influence on CD73 expression and adenosine levels. We demonstrate that mIDH1 glioma cells exhibit reduced CD73 expression, driven by DNA hypermethylation, leading to reduced adenosine levels. Since wtIDH1 gliomas have high CD73 expression, we evaluated CD73 blockade as an immunotherapy target. We show that CD73 inhibition used as monotherapy did not improve survival in wtIDH1 glioma-bearing mice. However, when combined with immune-stimulatory Ad-TK (adenoviral vectors encoding herpes simplex virus thymidine kinase) and Ad-Flt3L (adenoviral vectors encoding FMS-like tyrosine kinase 3 ligand) gene therapy, CD73 blockade significantly enhanced therapeutic efficacy and increased anti-glioma effector T cell activity. These findings reveal that CD73 inhibition used in combination with immune-stimulatory Ad-TK/Ad-Flt3L gene therapy may be an effective treatment for wtIDH1 gliomas, which could be readily translated to the clinical arena.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
- Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
- Department of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, MI 48109, USA.
- College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA.
- Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.
- Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109, USA.
Förderung
- National Cancer Institute
- Leah's Happy Hearts
- University of Michigan Rackham Graduate School
- Pediatric Brain Tumor Foundation of the United States Inc
- ChadTough Defeat DIPG Foundation
- Ian's Friends Foundation
- National Institutes of Health
- Rogel Cancer Center, University of Michigan
Zitieren
APA
McClellan, B. L., Peña Agudelo, J. A., Mujeeb, A. A., Dabaja, A. A., Zhu, Z., Raghuram, S., Varela, M. L., Tronrud, C., Banerjee, K., Wei, A., Calatroni, C., Zhang, L. H., Romero, L. C., Oh, P., Alghamri, M. S., Robbins, A., Perricone, M., Wang, Y., Shay, B., …, & Castro, M. G. (2026). Reprogramming the immune suppressive tumor microenvironment in glioma enhances the efficacy of immune-mediated gene therapy. Molecular Therapy Oncology, 34(2), 201215. https://doi.org/10.1016/j.omton.2026.201215
Vancouver
McClellan BL, Peña Agudelo JA, Mujeeb AA, Dabaja AA, Zhu Z, Raghuram S, et al. Reprogramming the immune suppressive tumor microenvironment in glioma enhances the efficacy of immune-mediated gene therapy. Molecular Therapy Oncology. 2026;34(2):201215. doi:10.1016/j.omton.2026.201215
BibTeX
@article{McClellan2026,
author = {McClellan, Brandon L and Peña Agudelo, Jorge A and Mujeeb, Anzar A and Dabaja, Ali A and Zhu, Ziwen and Raghuram, Sadhakshi and Varela, Maria Luisa and Tronrud, Claire and Banerjee, Kaushik and Wei, Abraham and Calatroni, Cecilia and Zhang, Lucia H and Romero, Lissa Cruz and Oh, Paul and Alghamri, Mahmoud S and Robbins, Andrew and Perricone, Matthew and Wang, Ying and Shay, Brian and Sajjakulnukit, Peter and Lyssiotis, Costas A and Welch, Joshua D and Schwendeman, Anna and Lowenstein, Pedro R and Castro, Maria G},
title = {Reprogramming the immune suppressive tumor microenvironment in glioma enhances the efficacy of immune-mediated gene therapy},
journal = {Molecular Therapy Oncology},
year = {2026},
volume = {34},
number = {2},
pages = {201215},
doi = {10.1016/j.omton.2026.201215}
}
EUVIMED